Author

J. Kolls

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Cell Biology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Organism:human· 3 Research Focus:drug response / drug discovery· 2 Research Focus:host-pathogen & immune response· 2 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1

Frequent Co-Authors

B. Beddingfield· 2 shared N. Iwanaga· 2 shared A. Mulay· 1 shared A. Purkayastha· 1 shared B. Gomperts· 1 shared B. Konda· 1 shared B. Stripp· 1 shared C. Garcia-de-Alba· 1 shared

Activity by Year

2020-2021 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 18 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

B. Beddingfield

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Antibody-induced glomerulonephritis is amplified by RTEC-intrinsic IL-17 signaling and restrained by IL-17-mediated induction of the endoribonuclease Regnase-1 (Zc3h12a)

D.-D. Li, R. Bechara, K. Ramani, C. Jawale, Y. Li, J. Kolls, S. Gaffen, P. S. Biswas

This study shows that IL-17 signaling in renal tubular epithelial cells drives antibody-induced glomerulonephritis, and Regnase-1 limits this inflammation by inhibiting IL-17 target genes.

bioRxiv · Jan 11, 2021 · PreprintImmunology

SARS-CoV-2 infection of primary human lung epithelium for COVID-19 modeling and drug discovery

A. Mulay, B. Konda, G. Garcia, C. Yao, S. Beil, C. Sen, A. Purkayastha, J. Kolls, D. Pociask, P. Pessina, C. Garcia-de-Alba, J. Sainz de Aja, C. Kim, B. Gomperts, V. Arumugaswami, B. Stripp

The paper develops a primary human lung epithelium infection model to study SARS-CoV-2 pathobiology and screen drugs for COVID-19.

bioRxiv · Jun 29, 2020Cell Biology

The Integrin Binding Peptide, ATN-161, as a Novel Therapy for SARS-CoV-2 Infection

B. Beddingfield, N. Iwanaga, P. P. Chapagain, W. Zheng, C. J. Roy, T. Y. Hu, J. Kolls, G. Bix

This paper explores ATN-161 as a potential therapy for SARS-CoV-2 by targeting the interaction between the spike protein and 5β1 integrin, alongside ACE2.

bioRxiv · Jun 15, 2020Microbiology

Novel ACE2-IgG1 fusions with improved in vitro and in vivo activity against SARS-CoV2

N. Iwanaga, L. Cooper, L. Rong, B. Beddingfield, J. Crabtree, R. A. Tripp, X. Qin, J. Kolls

This paper develops a modified ACE2-IgG1 fusion protein with enhanced in vivo activity against SARS-CoV2, showing improved lung bioavailability and viral neutralization.

bioRxiv · Jun 15, 2020 · PreprintImmunology